Imugene Limited
IUGNF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $3,138 | $1,258 | -$3,098 | $8,068 |
| % Growth | 149.5% | 140.6% | -138.4% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $3,138 | $1,258 | -$3,098 | $8,068 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $15,387 | $31,304 | $42,210 | $44,676 |
| G&A Expenses | $8,750 | $19,019 | $25,350 | $34,557 |
| SG&A Expenses | $8,750 | $19,019 | $25,350 | $34,557 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $113 | $764 | $11,895 | $0 |
| Operating Expenses | $24,250 | $51,087 | $79,455 | $79,233 |
| Operating Income | -$21,112 | -$49,829 | -$67,559 | -$86,159 |
| % Margin | -672.7% | -3,961% | 2,180.7% | -1,067.9% |
| Other Income/Exp. Net | $429 | $314 | -$9,960 | $13,997 |
| Pre-Tax Income | -$20,683 | -$49,515 | -$77,519 | -$72,162 |
| Tax Expense | $0 | -$1,176 | $3,447 | -$8,062 |
| Net Income | -$20,683 | -$48,339 | -$80,966 | -$68,715 |
| % Margin | -659% | -3,842.5% | 2,613.5% | -851.7% |
| EPS | -0.094 | -0.22 | -0.38 | -0.34 |
| % Growth | 57.2% | 42.1% | -11.8% | – |
| EPS Diluted | -0.094 | -0.22 | -0.38 | -0.34 |
| Weighted Avg Shares Out | 219,527 | 217,879 | 213,951 | 202,412 |
| Weighted Avg Shares Out Dil | 219,527 | 217,879 | 213,951 | 202,412 |
| Supplemental Information | – | – | – | – |
| Interest Income | $429 | $1,490 | $1,954 | $2,561 |
| Interest Expense | $0 | $0 | $213 | $265 |
| Depreciation & Amortization | $1,334 | $1,307 | -$0 | $1,859 |
| EBITDA | -$18,901 | -$48,522 | -$77,306 | -$69,152 |
| % Margin | -602.3% | -3,857.1% | 2,495.3% | -857.1% |